US judge rejects Novo bid to block Lilly weight-loss drug ads

A U.S. judge denied Novo Nordisk's request to block Eli Lilly's advertising campaign for weight-loss drugs, which Novo claims is deceptive. The ruling allows Lilly to continue its marketing, potentially intensifying competition in the GLP-1 market. The decision is a setback for Novo but does not resolve the underlying dispute.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works